Spravato® approved for treatment of depression

December 11, 2020

The nasal spray, Spravato® (esketamine), is covered when deemed medically necessary to treat beneficiaries with treatment-resistant depression and other US Food and Drug Administration (FDA)-approved indications, which are available in the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. Prior authorization is required.

Use Common Procedure Terminology (CPT) codes G2082-83 and Healthcare Common Procedure Coding System (HCPCS) code J3490.

See the TRICARE Policy Manual (TPM), Chapter 7, Section 3.8 for more information.